human
lung
transplant
first
perform
patient
surviv
oper
larg
abandon
advent
ciclosporin
develop
combin
heart
lung
transplant
nearli
year
later
today
lung
transplant
perform
procedur
firmli
establish
amongst
therapeut
option
avail
patient
sever
lung
diseas
donor
shortag
main
factor
limit
applic
drive
search
new
strategi
increas
number
lung
avail
transplant
includ
use
live
donor
eas
donor
select
criteria
ex
vivo
techniqu
recondit
lung
margin
viabil
lung
transplant
repeat
oper
perform
graft
failur
patient
receiv
lung
transplant
rang
infant
elderli
peak
age
year
princip
condit
treat
lung
transplant
adult
chronic
obstruct
pulmonari
diseaseemphysema
idiopath
pulmonari
fibrosi
cystic
fibrosi
antitrypsin
defici
primari
pulmonari
hypertens
remaind
includ
sarcoidosi
lymphangioleiomyomatosi
connect
tissu
diseas
rare
lung
cancer
commonest
indic
lung
transplant
adolesc
cystic
fibrosi
children
congenit
heart
diseas
combin
heart
lung
transplant
first
perform
follow
singlelung
transplant
doublelung
transplant
lastli
sequenti
bilater
lung
transplant
combin
oper
requir
total
cardiopulmonari
bypass
success
carri
risk
acceler
coronari
atheroma
problem
result
cardiac
denerv
howev
rel
simpl
technic
maintain
coronarytracheobronchi
arteri
anastomos
help
tracheal
anastomosi
heal
particularli
suitabl
heart
lung
damag
pulmonari
hypertens
cystic
fibrosi
necessari
replac
lung
avoid
risk
spillov
infect
doublelung
transplant
complex
procedur
initi
use
emphysema
fear
singlelung
transplant
nativ
diseas
lung
would
preferenti
ventil
prove
case
singlelung
transplant
wide
use
sever
emphysema
pulmonari
fibrosi
commonest
procedur
simplest
perform
associ
fewest
postop
complic
requir
least
amount
donor
tissu
enabl
greatest
number
recipi
benefit
singl
donor
immunosuppress
therefor
milit
success
transplant
aspergilloma
contraind
form
lung
transplant
attempt
remov
inevit
lead
seed
pleural
caviti
mediastinum
previou
thorac
surgeri
may
make
difficult
oper
possibl
futur
lung
transplant
therefor
born
mind
consid
best
treatment
condit
pneumothorax
left
ventricular
function
normal
near
normal
although
treatabl
coronari
arteri
diseas
absolut
contraind
ventil
support
prior
transplant
signific
risk
factor
pulmonari
neoplasia
gener
regard
contraind
earli
dissemin
bronchioloalveolar
carcinoma
term
adenocarcinomainsitu
often
limit
lung
doublelung
transplant
employ
treat
form
lung
cancer
contraind
less
import
includ
age
year
bodi
mass
index
usa
prioriti
given
patient
rapidli
progress
condit
idiopath
pulmonari
fibrosi
need
lung
transplant
achiev
numer
score
system
take
account
probabl
durat
surviv
without
transplant
compar
follow
transplant
system
introduc
result
increas
number
patient
idiopath
pulmonari
fibrosi
receiv
transplant
decreas
waitinglist
mortal
waitinglist
time
howev
high
score
predict
increas
morbid
mortal
follow
transplant
reflect
poor
clinic
condit
mani
patient
transplant
system
yet
wide
adopt
uk
organ
current
alloc
basi
proxim
time
wait
list
select
manag
donor
preserv
harvest
lung
crucial
reduc
impact
brainstem
death
except
bronchial
arteri
revascularis
undertaken
centr
attempt
made
reanastomos
sever
tracheal
bronchial
blood
vessel
nerv
oper
lymphat
also
sever
heart
includ
loss
structur
promot
postop
haemorrhag
breakdown
tracheal
bronchial
anastomosi
reduct
cough
reflex
pulmonari
oedema
aspect
lung
transplant
lymphat
tissu
inevit
includ
allograft
entail
risk
graftversushost
diseas
greatest
whole
mediastinum
transfer
combin
heart
lung
transplant
practic
rare
complic
mortal
associ
lung
transplant
constantli
diminish
techniqu
immunosuppress
improv
intern
societi
heartlung
transplant
report
surviv
rate
year
respect
lung
transplant
period
combin
heartlung
transplant
fig
first
postop
month
mortal
chiefli
due
sepsi
haemorrhag
poor
lung
preserv
first
month
princip
caus
death
infect
reject
form
oblit
bronchiol
lung
transplant
oper
last
resort
insuffici
donor
patient
unlik
consid
unless
measur
fail
shortterm
prognosi
otherwis
poor
presenc
uncontrol
system
diseas
preclud
consider
good
renal
hepat
function
essenti
particularli
view
immunosuppress
drug
toxic
particularli
import
antitrypsin
defici
cystic
fibrosi
may
affect
liver
directli
infect
elimin
either
oper
like
dissemin
postop
histopatholog
play
major
role
assess
postop
complic
transplant
contribut
manag
transplant
recipi
oper
box
accur
preoper
diagnosi
import
histopatholog
reassess
potenti
recipi
may
affect
choic
transplant
procedur
identifi
condit
treatabl
mean
need
erad
transplant
undertaken
may
also
predict
presenc
system
diseas
likelihood
origin
diseas
recur
allograft
detect
malign
diseas
apart
bronchioloalveolar
carcinoma
adenocarcinomainsitu
absolut
contraind
transplant
explant
lung
also
examin
without
delay
case
show
unsuspect
diseas
tuberculosi
sarcoidosi
malign
may
activ
elsewher
recipi
major
discrep
pretranspl
diagnosi
appar
examin
explant
report
case
similarli
one
donor
lung
use
examin
may
identifi
unsuspect
infect
diseas
like
also
present
graft
thu
histopathologist
concern
sole
assess
complic
undoubtedli
major
role
rest
chapter
larg
confin
aspect
transplant
assess
complic
least
five
piec
alveol
lung
examin
minimum
three
level
use
connect
tissu
fungal
stain
addit
haematoxylin
eosin
sequenti
sampl
common
possibl
observ
abnorm
due
previou
biopsi
alway
consid
also
import
rememb
pattern
lung
injuri
nonspecif
exampl
diffus
alveolar
damag
may
reflect
sever
reperfus
injuri
infect
acut
reject
may
requir
special
stain
infect
agent
consider
time
event
distinguish
caus
may
reject
infect
histolog
featur
overlap
biopsi
find
alway
interpret
light
clinic
radiolog
featur
previou
biopsi
find
result
current
microbiolog
serolog
investig
princip
complic
list
box
consid
lung
minimis
reimplant
injuri
brainstem
death
lead
adrenerg
system
hypertens
result
fluid
shift
lesser
circul
neurogen
pulmonari
oedema
injuri
part
generalis
releas
cytokin
inflammatori
mediat
damag
mani
organ
includ
lung
may
compound
caus
injuri
donat
cadav
lung
use
current
donor
select
criteria
includ
age
less
year
abo
compat
clear
chest
xray
airway
mucos
inflamm
bronchoscopi
histori
lung
contus
sever
chest
trauma
previou
cardiopulmonari
surgeri
aspir
donor
seroposit
cytomegaloviru
danger
seroneg
recipi
persist
hepat
b
c
antigenaemia
human
immunodefici
viru
infect
contraind
howev
mild
asthma
smoke
advers
affect
outcom
physiotherapi
bronchial
toilet
prophylact
antibiot
requir
monitor
blood
gase
pulmonari
wedg
pressur
import
manag
potenti
donor
harvest
lung
best
store
inflat
cool
flush
pulmonari
arteri
eurocollin
solut
ischaemia
toler
hour
donorrecipi
match
includ
approxim
similar
chest
size
although
volum
reduct
surgeri
may
circumv
signific
mismatch
one
lobe
adult
lung
may
use
replac
whole
lung
child
tissu
transplant
child
grow
normal
rate
potenti
recipi
screen
donorspecif
lymphocytox
antibodi
panel
hlaa
b
dr
antigen
result
consid
posit
recipi
serum
react
hla
antigen
panel
case
donorspecif
tand
blymphocytotox
antibodi
crossmatch
requir
posit
result
contraind
transplant
donor
associ
acceler
graft
reject
recipi
immun
suppress
combin
ciclosporin
azathiaprin
prednisolon
backup
provid
immunosuppress
drug
tacrolimu
mycophenol
mofetil
everolimu
sirolimu
drug
sideeffect
notabl
renal
hepat
bone
marrow
toxic
increas
risk
neoplasia
antithymocyt
globulin
seldom
use
cyclophosphamid
plasmaphoresi
reserv
use
antibodymedi
reject
lowdos
septrin
administ
prophylact
pneumocysti
infect
frequent
monitor
lung
transplant
recipi
essenti
first
month
transplant
risk
main
complic
acut
reject
infect
greatest
recipi
undergo
frequent
clinic
review
bronchoscopi
undertaken
respons
symptom
radiograph
chang
unexplain
fever
sudden
deterior
lung
function
bronchoalveolar
lavag
transbronchi
biopsi
gener
perform
lavag
particularli
use
detect
infect
transbronchi
lung
biopsi
despit
falseneg
rate
mainstay
diagnosi
allograft
reject
centr
schedul
biopsi
wherea
other
biopsi
symptom
dictat
reject
heart
combin
heart
lung
transplant
recipi
rare
box
role
histopathologist
lung
transplant
diagnosi
underli
diseas
transplant
examin
explant
lung
verifi
diagnosi
identifi
diseas
examin
unus
donor
tissu
biopsi
assess
posttranspl
complic
postmortem
examin
well
contribut
outcom
transplant
histopathologist
well
place
undertak
collabor
research
fortun
rare
common
develop
exuber
granul
tissu
may
serious
narrow
airway
requir
endoscop
remov
cryotherapi
late
airway
complic
includ
stenosi
bronchomalacia
fig
requir
insert
stent
postop
obstruct
pulmonari
arteri
anastomosi
rare
kink
may
occur
vessel
long
usual
develop
first
week
may
diagnos
ventil
perfus
scan
arteriographi
venou
obstruct
may
also
develop
earli
transplant
especi
size
mismatch
lead
torsion
small
donor
lung
vascular
pedicl
result
may
thrombosi
one
pulmonari
vein
infarct
correspond
lobe
fig
system
embolis
may
also
occur
thrombu
extend
left
atrium
fragment
diagnosi
transoesophag
echocardiographi
earli
even
oper
goe
well
surgic
complic
earli
postop
period
often
mark
temporari
period
dyspnoea
chest
radiograph
time
often
show
hilar
opacif
biopsi
undertaken
gener
show
pulmonari
oedema
accompani
mild
neutrophil
exud
fig
chang
term
reimplant
injuri
various
attribut
deterior
graft
surgic
trauma
ischaemia
sever
pulmonari
lymphat
releas
free
radic
chemokin
neutrophil
interact
graft
endothelium
damag
ischaemia
usual
appear
within
hour
peak
day
slowli
settl
lymphat
regener
lung
drainag
reestablish
sever
chang
includ
diffus
alveolar
damag
term
primari
graft
failur
appli
may
repres
reimplant
respons
reject
infect
occur
obviou
caus
risk
factor
includ
relat
donor
advanc
age
smoke
histori
prolong
ventil
durat
ischaemia
recipi
transplant
pulmonari
hypertens
pulmonari
fibrosi
oper
cardiopulmonari
bypass
excess
use
blood
product
primari
graft
failur
may
progress
parenchym
fibrosi
associ
reduc
surviv
year
airway
infect
promot
slow
recoveri
mucociliari
clearanc
may
also
complic
earli
postop
period
alveolar
proteinosi
unusu
neutrophilrich
pattern
mix
interstiti
pneumon
also
describ
complic
involv
airway
anastomosi
apart
combin
heartlung
procedur
lung
transplant
inevit
involv
sever
tracheobronchi
blood
suppli
donor
airway
receiv
retrograd
pulmonari
arteri
blood
new
bronchial
arteri
anastomos
develop
surpris
therefor
poor
heal
airway
anastomosi
seriou
complic
although
bronchial
arteri
revascularis
perform
centr
time
transplant
render
less
common
anastomosi
also
subject
infect
surfac
epithelium
heal
mucociliari
clearanc
recov
denerv
contribut
risk
infect
elimin
cough
reflex
promot
aspir
dehisc
airway
anastomosi
devast
earli
complic
one
along
vessel
wall
alveolar
space
strongli
posit
iggmedi
lymphocytotox
reaction
donor
andor
b
lymphocyt
acut
reject
characteris
clinic
dyspnoea
fever
hypoxaemia
pleuropulmonari
opacif
fig
frequent
first
postop
year
typic
develop
within
month
oper
sometim
within
week
sever
year
later
acut
chronic
reject
classifi
grade
accord
intern
agre
histolog
criteria
box
acut
reject
may
centr
blood
vessel
airway
predominantli
affect
former
surround
lung
parenchyma
vascular
chang
class
treat
separ
involv
airway
class
b
latter
may
also
reflect
chronic
infect
ischaemia
aspir
chronic
reject
histolog
vascular
chang
characteris
infiltr
variabl
intens
compris
small
lymphocyt
plasma
cell
histiocyt
occasion
neutrophil
surround
small
blood
vessel
infiltr
adjac
alveolar
interstitium
grade
minim
grade
hardli
discern
without
high
magnif
mild
grade
evid
low
magnif
consist
infiltr
includ
larg
activ
lymphocyt
pyroninophil
cytoplasm
angul
nuclei
neutrophil
eosinophil
also
seen
infiltr
vascular
intima
lymphocyt
intim
endotheli
endotheli
cell
show
hyperplasia
moder
acut
reject
grade
characteris
extens
infiltr
alveolar
interstitium
sever
grade
acut
reject
usual
fatal
infiltr
widespread
accompani
haemorrhag
oedema
increas
number
alveolar
macrophag
fibrin
exud
hyalin
membran
destruct
chang
typic
recognit
potenti
catastroph
complic
essenti
earli
surgic
intervent
salvag
graft
patient
achiev
mechan
underli
lung
allograft
reject
fulli
understood
process
probabl
initi
tcell
recognit
histocompat
antigen
surfac
donor
cell
brunt
reject
damag
blood
vessel
airway
presum
reflect
increas
express
histocompat
antigen
pulmonari
vascular
endothelium
airway
epithelium
shown
follow
transplant
incompat
follow
activ
sequestr
platelet
neutrophil
macrophag
within
pulmonari
capillari
releas
reactiv
oxygen
speci
inflammatori
cytokin
increas
express
endothelin
induc
nitric
oxid
synthas
reject
process
probabl
involv
antibodi
cellmedi
immun
mechan
extent
contribut
vari
hyperacut
reject
gener
regard
antibodymedi
wherea
acut
chronic
reject
thought
predominantli
cellmedi
hyperacut
reject
occur
within
hour
transplant
caus
reaction
preform
antibodi
donor
endotheli
cell
characteris
mark
congest
oedema
result
product
copiou
frothi
bloodstain
fluid
bronchial
orific
allograft
risk
factor
includ
multipl
blood
transfus
pregnanc
surgeri
previou
transplant
necessit
donorspecif
pretranspl
tand
blymphocytotox
antibodi
crossmatch
see
microscopi
show
mark
pulmonari
congest
oedema
alveolar
haemorrhag
vascular
thrombosi
neutrophil
infiltr
endotheli
epitheli
damag
ultim
diffus
alveolar
damag
fig
diagnosi
confirm
detect
immunofluoresc
complement
split
product
marker
complement
activ
igg
deposit
endothelium
b
may
coexist
may
c
nose
grade
absenc
infect
opportunist
infect
may
viral
particularli
herp
simplex
cytomegaloviru
distinct
inclus
may
modifi
prior
antivir
treatment
therefor
difficult
identifi
fig
howev
infiltr
viral
infect
gener
extens
pattern
predominantli
interstiti
pneumon
secondari
involv
vessel
perivascular
lymphoid
infiltr
may
also
seen
pneumocysti
jirovecii
pneumonia
fungal
bacteri
infect
necessit
special
stain
difficult
case
immunocytochemistri
situ
hybridis
eosinophil
pneumonia
uncommon
manifest
graft
reject
accept
infect
organ
aspergillu
exclud
predominantli
neutrophil
infiltr
necrosi
granuloma
format
favour
infect
rather
reject
acut
reject
also
distinguish
ischaemiareperfus
injuri
describ
lymphoprolif
disord
describ
ischaemiareperfus
injuri
lack
perivascular
interstiti
infiltr
reject
polymorph
perivascular
infiltr
b
lymphocyt
predomin
latter
favour
reject
rather
lymphodiffus
alveolar
damag
fig
grade
reject
may
also
associ
organis
pneumonia
success
suppress
reject
followup
biopsi
show
reduct
infiltr
term
resolv
rejectionlow
grade
chang
makeup
mixtur
small
lymphocyt
haemosiderinladen
macrophag
term
resolv
reject
grade
immunohistochemistri
show
major
lymphoid
cell
lymphocyt
fig
often
pyroninophil
may
express
lymphocyt
activ
antigen
prolifer
antigen
b
lymphocyt
usual
spars
larger
number
may
reflect
reject
base
humor
rather
cellular
mechan
therefor
predict
poor
respons
usual
cellbas
immunosuppress
regim
howev
presenc
also
prompt
consider
entiti
eosinophil
pneumonia
fungal
infect
lymphoprolif
diseas
vascular
endothelium
alveolar
epithelium
show
upregul
class
ii
hla
hladr
antigen
although
perivascular
lymphoid
cell
infiltr
hallmark
acut
reject
similar
infiltr
may
seen
patient
infect
condit
augment
immunosuppress
inappropri
reason
acut
reject
diag
histolog
featur
constrict
bronchiol
obliteran
typic
concentr
eccentr
hyalin
fibrou
thicken
bronchiolar
submucosa
encroach
airway
lumen
eventu
result
total
occlus
fig
chang
may
subtl
case
elastin
stain
invalu
identifi
fibros
bronchiol
residu
bronchiolar
epithelium
may
show
squamou
metaplasia
usual
disrupt
muscl
coat
process
may
activ
ie
associ
lymphocyt
bronchiol
inact
consist
dens
fibrou
scar
minim
inflamm
although
prognost
signific
predict
respons
treatment
infiltr
cell
lymphocyt
process
patchi
therefor
alway
evid
small
biopsi
presenc
may
suggest
obstruct
featur
accumul
foami
macrophag
distal
air
space
current
classif
constrict
bronchiol
simpli
record
present
absent
recognit
bronchiol
obliteran
key
discrimin
acut
chronic
reject
adjac
lung
may
also
show
prolif
diseas
characteris
monomorph
infiltr
larg
b
lymphocyt
mass
lesion
also
favour
lymphoprolif
diseas
infect
rather
reject
recurr
allograft
diseas
sarcoidosi
langerhan
cell
histiocytosi
may
also
misinterpret
acut
reject
characterist
featur
well
repres
airway
inflamm
form
lymphocyt
bronchiol
major
pattern
acut
reject
evid
repres
reject
includ
progress
chronic
reject
bronchiol
obliteran
frequent
respons
augment
immunosuppress
may
accompani
succeed
perivascular
infiltr
describ
seen
alon
frequent
follow
vascular
chang
airway
inflamm
may
grade
way
perivascular
infiltr
practic
small
size
biopsi
gener
preclud
precis
requir
chang
rang
spars
airway
cuf
small
lymphoid
cell
grade
diffus
infiltr
lamina
propria
epithelium
medium
larg
lymphoid
cell
epitheli
apoptosi
grade
fig
sever
case
lymphoid
infiltr
particularli
dens
ulcer
fibrinopurul
exud
import
largeairway
inflamm
reject
unclear
often
secondari
infect
grade
airway
inflamm
therefor
current
restrict
bronchiol
differenti
diagnosi
airway
inflamm
includ
presenc
bronchusassoci
lymphoid
tissu
donor
origin
lowgrad
infect
consequ
aspir
bronchusassoci
lymphoid
tissu
distinguish
compris
aggreg
b
lymphocyt
sometim
admix
anthracot
macrophag
contrast
tcellrich
infiltr
reject
promin
neutrophil
eosinophil
infiltr
suggest
infect
aspir
howev
import
note
airway
parenchym
infect
notabl
cytomegaloviru
may
accompani
reject
chronic
reject
transplant
lung
mark
progress
breathless
cough
often
product
fever
declin
lung
function
chang
monitor
spirometri
imag
fig
centr
bronchiol
class
c
blood
vessel
class
de
novo
antihla
antibodi
follow
transplant
also
associ
increas
incid
bronchiol
obliteran
suggest
humor
reject
may
play
role
gastrooesophag
reflux
chronic
airway
infect
may
also
contribut
develop
oblit
bronchiol
caus
includ
cytomegaloviru
infect
communityacquir
viral
infect
ischaemia
final
suggest
earli
case
characteris
acut
inflamm
biopsi
lavag
absenc
infect
respond
well
azithromycin
therapi
socal
neutrophil
revers
allograft
dysfunct
pathogenesi
oblit
fibrosi
yet
fulli
elucid
intrigu
cell
particip
fibrosi
deriv
circul
fibroblast
precursor
recipi
bone
marrow
origin
also
evid
suggest
role
epithelialmesenchym
transit
scleros
process
chronic
reject
may
also
involv
pulmonari
vasculatur
result
fibrointim
sclerosi
arteri
vein
analog
occur
coronari
arteri
heart
heartlung
allograft
fig
uncommon
complic
may
activ
inact
may
seen
associ
oblit
bronchievid
concomit
acut
reject
fig
patient
bronchiol
obliteran
also
bronchiectasi
fig
probabl
result
combin
factor
includ
reject
infect
denerv
concomit
acut
airway
inflamm
suggest
postobstruct
infect
unfortun
sampl
error
render
diagnosi
bronchiol
obliteran
unreli
small
biopsi
identif
gener
depend
upon
recognit
bronchiol
obliteran
syndrom
defin
graft
deterior
due
progress
airway
diseas
caus
princip
role
transbronchi
lung
biopsi
therefor
exclud
treatabl
caus
deterior
lung
function
bronchiol
obliteran
seldom
seen
within
month
oper
incid
diminish
year
affect
recipi
year
risk
factor
includ
earlier
reject
episod
histocompat
mismatch
support
view
repres
late
manifest
reject
immunolog
pathogenesi
analog
occur
rheumatoid
graftversushost
diseas
see
p
develop
oliti
would
domin
clinic
pictur
sclerosi
small
vessel
may
also
repres
chronic
reject
gener
disregard
may
also
follow
ischaemia
acut
reject
nonrejectionrel
pulmonari
inflamm
nonspecif
donorrel
factor
hyperacut
reject
archetyp
form
antibodymedi
reject
preform
antibodi
crossreact
graft
antigen
result
fulmin
reject
howev
known
renal
cardiac
transplant
less
acut
form
antibodymedi
reject
may
occur
criteria
diagnos
includ
presenc
de
novo
donorspecif
antibodi
clinic
allograft
dysfunct
histolog
featur
antibodymedi
reject
deposit
complement
protein
stabl
biproduct
complement
activ
capillari
endothelium
role
antibodymedi
reject
lung
allograft
reject
far
clear
report
lung
transplant
patient
mani
featur
antibodymedi
reject
treat
success
plasmapheresi
intraven
immunoglobulin
suggest
capillar
may
repres
antibodymedi
reject
current
consensu
histolog
featur
defin
condit
lung
furthermor
deposit
may
seen
lung
primari
graft
failur
infect
limit
use
marker
reject
remain
elucid
recent
work
reveal
complex
interact
compon
complement
system
platelet
endotheli
cell
well
evid
suggest
influenc
complement
b
lymphocyt
function
endotheli
activ
appear
play
central
role
develop
antibodymedi
reject
work
may
provid
specif
sensit
marker
seriou
complic
lung
transplant
humor
reject
progress
upperlob
fibrosi
occasion
describ
lung
transplant
imag
show
interlobular
septal
thicken
groundglass
chang
progress
traction
bronchiectasi
honeycomb
biopsi
show
nonspecif
inflamm
fibrosi
research
requir
determin
whether
provision
clinicopatholog
entiti
relat
reject
factor
infect
major
hazard
immunosuppress
recipi
lung
allograft
often
multipl
may
affect
nativ
lung
organ
well
allograft
recognit
lung
larg
depend
upon
microbiolog
examin
bronchoalveolar
lavag
fluid
addit
transbronchi
lung
biopsi
increas
detect
rate
problem
biopsi
interpret
includ
distinguish
reject
infect
compound
atyp
host
respons
immunosuppress
patient
distinguish
colonis
subclin
infect
clinic
signific
diseas
may
also
difficult
patholog
pulmonari
infect
describ
chapter
special
circumst
associ
transplant
warrant
comment
infect
agent
cytomegaloviru
infect
seroneg
recipi
transmit
blood
transfus
graft
increas
incid
reject
probabl
promot
express
major
histocompat
antigen
alveolar
epithelium
recognit
clinic
signific
diseas
oppos
mere
carriag
viru
base
upon
identif
blood
cytomegaloviru
antigen
biopsi
evid
interstiti
pneumon
bronchiol
fig
detect
viru
latter
often
requir
immunohistochemistri
molecular
techniqu
polymeras
chain
reaction
earli
stage
infect
typic
viral
inclus
often
spars
fig
later
stage
numer
intranuclear
cytoplasm
inclus
fig
pattern
cytomegaloviru
diseas
includ
poorli
form
granuloma
diffus
alveolar
damag
mass
lesion
simul
tumour
viral
prophylaxi
may
result
fragment
inclus
acut
neutrophil
pneumon
see
fig
infect
herp
simplex
viru
infrequ
lung
allograft
recipi
may
caus
necrotis
tracheobronch
pneumonia
patient
similarli
infect
influenza
respiratori
syncyti
virus
may
caus
signific
morbid
contribut
develop
bronchiol
obliteran
viral
infect
lung
allograft
toxoplasma
gondii
rare
larg
elimin
seroneg
solidorgan
transplant
recipi
given
posit
organ
prophylaxi
pyrimethamin
usual
occur
part
system
infect
follow
graft
mismatch
identif
organ
biopsi
materi
may
difficult
cyst
gondii
spars
extracellular
tachyzoit
may
mistaken
haematoxyphil
debri
see
fig
p
diagnosi
may
confirm
immunohistochemistri
polymeras
chain
reaction
appli
tissu
bodi
fluid
peripher
blood
aspir
gastrooesophag
reflux
aspir
fairli
common
follow
lung
transplant
increasingli
recognis
risk
factor
develop
oblit
bronchiol
repeat
episod
epitheli
injuri
histolog
featur
gener
nonspecif
activ
chronic
inflamm
although
foreignbodi
giant
cell
reaction
aspir
materi
occasion
allow
definit
diagnosi
see
fig
p
bronchoalveolar
lavag
studi
suggest
aspir
bile
salt
rather
gastric
acid
relat
subsequ
develop
oblit
bronchiol
reject
neoplasia
signific
factor
limit
longterm
surviv
solidorgan
transplant
rang
incid
tumour
may
aris
de
novo
inadvert
introduc
within
allograft
often
particularli
aggress
predispos
factor
addit
immunosuppress
includ
ultraviolet
irradi
activ
oncogen
virus
epsteinbarr
viru
papillomaviru
herpesviru
molecular
techniqu
shown
tumour
appar
aris
de
novo
may
donor
rather
recipi
origin
frequent
encount
de
novo
tumour
includ
posttransplant
lymphoprolif
disord
dealt
see
cutan
tumour
notabl
squamou
carcinoma
preced
premalign
skin
lesion
often
multipl
carcinoma
frequent
metastasis
may
contain
papillomaviru
intraepitheli
neoplasia
squamou
carcinoma
uterin
cervix
vulva
perineum
also
associ
human
papillomaviru
infect
may
occur
tumour
reput
occur
greater
frequenc
gener
popul
includ
carcinoma
kidney
hepatobiliari
tract
lung
last
often
present
advanc
stage
donor
origin
cytolog
specimen
bronchi
often
show
epitheli
atypia
often
reactiv
malign
tumour
seen
commonli
lung
transplant
recipi
gener
popul
includ
kaposi
sarcoma
lowgrad
leiomyosarcoma
singlelung
transplant
recipi
develop
bronchogen
carcinoma
within
nativ
lung
may
reflect
larg
number
transplant
perform
smokingrel
diseas
emphysema
idiopath
pulmonari
fibrosi
role
immunosuppress
develop
tumour
unclear
notabl
behav
aggress
spectrum
lymphoprolif
disord
may
complic
transplant
mani
organ
includ
lung
communityacquir
respiratori
virus
rhinoviru
enteroviru
coronaviru
respiratori
syncyti
viru
parainfluenza
viru
influenza
b
adenoviru
infect
lung
tran
plant
recipi
sever
vari
mild
upper
respiratori
tract
diseas
sever
pneumonia
complic
bacteri
fungal
superinfect
studi
link
infect
onset
acut
chronic
reject
featur
biopsi
often
nonspecif
interstiti
pneumon
occasion
specif
viral
cytopath
effect
may
seen
biopsi
adenoviru
see
p
usual
viral
cultur
requir
identifi
organ
molecular
techniqu
appli
lavag
materi
greatli
enhanc
sensit
specif
viral
diagnosi
opportunist
mycobacteria
origin
either
donor
recipi
infect
lung
allograft
recipi
rare
occas
mere
colonis
graft
without
caus
diseas
bacteri
infect
patient
includ
nocardiosi
legionella
pneumonia
pneumocysti
jirovecii
pneumonia
rare
lung
transplant
chemoprophylaxi
report
incid
less
mostli
follow
immunosuppress
increas
acut
reject
histolog
pattern
includ
predominantli
lymphoplasmacyt
interstiti
pneumon
scanti
exud
granulomat
pneumon
fungal
cyst
spars
classic
foami
alveolar
exud
rare
encount
perivascular
compon
lymphoplasmacyt
pattern
resembl
acut
reject
henc
mandatori
use
silver
stain
techniqu
transbronchi
lung
allograft
biopsi
routin
screen
bronchoalveolar
lavag
specimen
use
immunocytochemistri
polymeras
chain
reaction
fungi
infect
lung
allograft
patient
includ
candida
aspergillu
agent
may
mere
colonis
airway
caus
ulcer
tracheobronch
dehisc
anastomosi
bronchocentr
granulomatosi
cavit
pneumonia
mediastin
multipl
haematogen
abscess
granulomatosi
earli
lesion
may
rich
matur
plasma
cell
show
chang
suggest
infecti
mononucleosi
polymorph
infiltr
often
includ
plasmacytoid
cell
fig
monomorph
infiltr
may
consist
transform
blast
centroblastlik
centrocytelik
cell
immunoblast
show
high
prolifer
index
fig
singlecel
necrosi
common
histiocyt
lymphocyt
often
cuff
lesion
infiltr
bronchiolar
epithelium
uninvolv
lung
may
show
patchi
organis
pneumonia
immunoglobulin
clonal
variabl
earli
lesion
tend
polyclon
monomorph
lesion
usual
monoclon
polymorph
lesion
may
either
polyclon
monoclon
reduct
immunosuppress
treatment
antivir
agent
usual
lead
rapid
resolut
relaps
frequent
may
requir
radiat
treatment
chemotherapi
newer
less
toxic
treatment
cytotox
tlymphocyt
infus
antibodi
b
cell
rituximab
avail
graftversushost
diseas
transplant
lung
heartlung
block
contain
signific
amount
lymphoid
tissu
rare
occas
rash
coliti
pancytopenia
liver
dysfunct
may
suggest
graftversushost
diseas
develop
identif
donor
lymphocyt
blood
bronchoalveolar
lavag
fluid
patient
support
possibl
graftversushost
diseas
tend
develop
earli
postop
period
may
sever
fortun
rare
usual
respond
increas
immunosuppress
graftversushost
diseas
bone
marrow
transplant
may
caus
constrict
oblit
bronchiol
indistinguish
seen
lung
reject
cours
lung
transplant
donor
lung
spare
complic
biopsi
diagnosi
gener
depend
upon
histolog
appear
skin
rather
lung
diagnosi
may
immunosuppress
would
appear
underli
escap
normal
control
similar
diseas
seen
condit
characteris
profound
immunosuppress
acquir
immunodefici
syndrom
aid
exampl
epsteinbarr
viru
suspect
play
part
causat
lesion
identifi
mani
immunostain
applic
molecular
probe
incid
lymphoprolif
diseas
higher
recipi
seroneg
epsteinbarr
viru
oper
suggest
viral
infect
primari
rather
repres
reinfect
reactiv
latent
diseas
viru
detect
often
earli
late
diseas
notabl
featur
lesion
potenti
revers
immunosuppress
reduc
posttransplant
lymphoprolif
disord
describ
associ
virtual
current
use
immunosuppress
agent
thought
result
uncontrol
prolifer
epsteinbarr
virusimmortalis
b
cell
due
loss
cytotox
tcell
control
solidorgan
transplant
lymphoprolifer
usual
involv
cell
recipi
origin
contrast
bone
marrow
transplant
lymphoprolif
disord
gener
involv
cell
donor
origin
nevertheless
often
first
present
allograft
risk
factor
includ
type
transplant
young
age
multipl
reject
episod
multiag
immunosuppress
antitcel
therapi
pretranspl
epsteinbarr
viru
seroneg
interv
lung
transplant
develop
lymphoprolif
process
gener
short
median
time
month
median
time
death
month
incid
posttransplant
lymphoprolif
disord
rang
bone
marrow
kidney
transplant
nearli
lung
heartlung
intestin
thought
reflect
rel
higher
level
immunosuppress
requir
lung
intestin
transplant
posttransplant
lymphoprolif
diseas
may
involv
lung
isol
part
dissemin
diseas
lung
may
also
involv
posttransplant
lymphoprolif
diseas
recipi
solidorgan
transplant
diseas
may
asymptomat
caus
cough
fever
malais
radiograph
may
show
diffus
infiltr
singl
multipl
nodul
high
serum
level
epsteinbarr
viru
dna
predict
develop
posttranspl
lymphoprolif
diseas
tissu
examin
epsteinbarr
viru
immunocytochemistri
situ
hybridis
cell
phenotyp
immunoglobulin
clonal
lesion
cla
sifi
accord
scheme
advoc
world
health
organ
box
clinic
suspicion
posttransplant
lymphoprolif
diseas
convey
pathologist
tissu
snapfrozen
appropri
molecular
studi
synchron
metachron
lesion
investig
variat
clonal
morpholog
occur
within
individu
lesion
simultan
subsequ
lesion
difficulti
encount
diagnosi
especi
core
biopsi
stem
small
size
sampl
crush
artefact
extens
necrosi
caus
angioinvas
differenti
diagnosi
includ
infect
cytomegaloviru
pneumocysti
inflamm
caus
previou
biopsi
presenc
bronchusassoci
lymphoid
tissu
transplant
lung
acut
allograft
reject
rare
graftversushost
diseas
chief
pulmonari
manifest
posttransplant
lymphoprolif
diseas
lymphoid
hyperplasia
lymphoid
interstiti
pneumonia
full
spectrum
lymphoma
describ
chapter
predominantli
involv
b
lymphocyt
wherea
lymphocyt
predomin
infiltr
characteris
reject
highgrad
lymphoma
often
show
angioinvas
extens
necrosi
therebi
resembl
lymphomatoid
box
world
health
organ
classif
posttransplant
lymphoprolif
disord
ptld
reactiv
plasmacyt
hyperplasia
infecti
mononucleosislik
lesion
polyclon
rare
monoclon
ptld
monomorph
classifi
accord
lymphoma
resembl
diffus
larg
bcell
lymphoma
burkitt
lymphoma
plasma
cell
myeloma
plasmacytomalik
lesion
peripher
tcell
lymphoma
otherwis
categoris
hepatosplen
tcell
lymphoma
notabl
wherea
asthma
appear
cure
lung
transplant
may
also
transfer
transplant
lung
asthmat
donor
nonatop
patient
sarcoidosi
recur
graft
case
seldom
clinic
signific
diseas
recur
graft
includ
emphysema
antitrypsindefici
recipi
giant
cell
interstiti
pneumonia
hardmet
worker
desquam
interstiti
pneumonia
panbronchiol
alveolar
proteinosi
langerhan
cell
histiocytosi
lymphangioleiomyomatosi
last
diseas
almost
entir
confin
women
notabl
donor
lung
affect
recurr
diseas
men
recurr
smoothmuscl
prolifer
recipi
origin
immun
cell
contribut
recurr
sarcoidosi
recurr
bronchioloalveolar
cell
carcinoma
shown
origin
recipi
recurr
taken
place
despit
lung
replac
evid
extrapulmonari
involv
idiopath
pulmonari
fibrosi
emphysema
exampl
diseas
yet
report
recur
transplant
lung
immunosuppress
drug
use
maintain
transplant
may
harm
organ
exampl
ciclosporin
may
caus
renal
damag
rhabdomyolysi
azathioprin
may
damag
liver
bone
marrow
sever
pattern
lung
diseas
describ
recipi
lung
organ
transplant
follow
treatment
sirolimu
includ
lymphocyt
interstiti
pneumonia
organis
pneumonia
diffus
alveolar
haemorrhag
pulmonari
haemorrhag
sirolimu
also
contraind
postop
may
caus
dehisc
bronchial
anastomosi
amiodaron
may
use
treat
atrial
fibril
common
postop
complic
rare
case
amiodaron
lung
report
transplant
recipi
increas
number
patient
await
lung
transplant
limit
donor
pool
pressur
transplant
centr
immens
advanc
medic
treatment
pulmonari
condit
patient
often
transplant
cystic
fibrosi
pulmonari
hypertens
fibros
lung
diseas
reduc
demand
transplant
servic
new
strategi
requir
explor
includ
attempt
improv
condit
borderlin
lung
use
mechan
assist
devic
xenotransplant
construct
new
lung
bioengin
far
strategi
enter
clinic
arena
recondit
ex
vivo
wherebi
condit
borderlin
donor
lung
improv
mechan
ventil
perfus
special
design
circuit
stem
cell
therapi
may
also
prove
benefit
recondit
borderlin
lung
mechan
assist
devic
wellestablish
role
endstag
heart
failur
use
devic
support
patient
await
lung
transplant
limit
extracorpor
membran
oxygen
use
success
shortterm
bridg
transplant
patient
develop
portabl
artifici
lung
longer
support
outsid
hospit
still
await
pulmonari
xenotransplant
area
activ
research
sever
group
explor
use
porcin
lung
confirm
demonstr
donor
recipi
chimer
hla
type
peripher
blood
lymphocyt
bronchoalveolar
lavag
fluid
system
effect
underli
diseas
cystic
fibrosi
may
signific
impact
recoveri
recurr
allograft
consid
aetiolog
mani
diseas
treat
lung
transplant
imperfectli
understood
knowledg
broaden
behaviour
follow
transplant
diseas
prone
recur
new
lung
wherea
other
particular
interest
find
lung
transplant
patient
cystic
fibrosi
appear
develop
basic
defect
membran
transport
underli
diseas
also
